Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken,…
The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device…
The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that…
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other…
The pharmaceutical and medical devices industries are both classified as emerging sectors by the Ministry of Economy. The undersecretary of industry and commerce discusses the importance of the sectors to…
In public health everything is a priority. The Undersecretary of Prevention and Health Promotion explains how Mexico’s Ministry of Health is handling the country’s changing epidemiological profile without forgetting communicable…
The implementation of third authorized parties has been a very proactive effort implemented by Mexico’s regulatory authority Cofepris to expedite the time to issue sanitary registrations. The CEO of Entimem…
Starting a new business is no easy task. The general manager of Alliance SFA shares his experience, how he decided to focus on second-tier and niche players to offer tailor-made…
Founded back in 1956, Laboratorios Keton is a small 100 percent Mexican company committed to provide high-quality contract manufacturing services to local as well as international drug makers. With more…
See our Cookie Privacy Policy Here
